Cancer/testis antigen 1 (ORF2 (18-27))

Cancer/testis antigen 1 (ORF2 (18-27)) is a synthetic peptide fragment derived from the open reading frame 2 region of the cancer/testis antigen 1 protein, a well-characterized member of the cancer/testis antigen family. These antigens are notable for their restricted expression patterns—typically limited to the testis in normal tissues but aberrantly activated in various malignancies—making them highly relevant to oncological and immunological research. The 18-27 amino acid sequence represents a defined epitope within the ORF2 region, offering a valuable tool for studies focused on antigen processing, T cell recognition, and the molecular mechanisms underlying tumor-associated antigenicity.

Epitope mapping: The peptide is widely utilized in epitope mapping experiments to delineate the specific regions of cancer/testis antigen 1 that are recognized by the immune system. By incorporating this defined sequence into immunoassays or cellular assays, researchers can precisely identify T cell epitopes and characterize the peptide's immunogenic potential. This facilitates the understanding of antigen presentation dynamics and aids in the discovery of novel immunological targets within the cancer/testis antigen family.

T cell activation studies: As a well-defined peptide epitope, the product serves as a potent stimulus for in vitro T cell activation assays. When presented by antigen-presenting cells, it can be used to evaluate the specificity, avidity, and functionality of cytotoxic T lymphocytes or helper T cells recognizing the cancer/testis antigen 1. These studies are essential for elucidating mechanisms of immune recognition and for validating candidate peptides for immunological research applications.

Peptide-MHC binding analysis: The defined sequence of this peptide makes it an ideal substrate for investigating peptide-MHC binding affinities and stability. Using binding assays or structural studies, researchers can assess how the ORF2 (18-27) fragment interacts with various major histocompatibility complex molecules. Such experiments provide insights into the molecular determinants of antigen presentation and can inform the rational design of peptide-based reagents for immunological assays.

Synthetic peptide control: In experimental workflows involving peptide pools or antigen-specific stimulation, the product functions as a reliable synthetic control. Its well-characterized sequence and reproducible properties allow it to serve as a benchmark for assay optimization, validation of peptide synthesis protocols, and standardization of immune monitoring techniques. Employing this peptide as a reference ensures experimental consistency and enhances the interpretability of immunological data.

Structural and functional studies: The availability of the Cancer/testis antigen 1 (ORF2 (18-27)) peptide supports structural biology investigations aimed at elucidating peptide conformation, stability, and interactions with immune receptors. By enabling crystallographic, spectroscopic, or computational analyses, the peptide contributes to a deeper understanding of the structural features that govern antigenicity and immune recognition within the cancer/testis antigen family. Such insights are critical for advancing knowledge in tumor immunology and the molecular basis of immune surveillance.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

3. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis

4. Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide

5. Myotropic activity of allatostatins in tenebrionid beetles